Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Stock-based Compensation (Tables)

Note 13 - Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

										*Weighted-*
										*Average*
						*Weighted-*				*Remaining*				*Aggregate*
		*Stock*				*Average*				*Contractual*				*Intrinsic*
		*Awards*				*Exercise Price*				*Life (Years)*				*Value*
Balance as of December 31, 2022			270			$	37.96
Options forfeited			—				—
Options cancelled			(16	)			55.91
Balance as of September 30, 2023			254			$	36.89				4.66			$	—
Vested and expected to vest as of September 30, 2023			254			$	36.89				4.66			$	—
Exercisable as of September 30, 2023			253			$	37.07				4.66			$	—

Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]

						*Weighted-*
		*Number of*				*Average Grant*
		*Shares*				*Date Fair Value*
Unvested as of December 31, 2022			1,383			$	2.17
Granted			873				1.37
Vested			(750	)			2.11
Forfeited			(32	)			1.53
Unvested as of September 30, 2023			1,474			$	2.26

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		*Three Months Ended September 30,*								*Nine Months Ended September 30,*
		*2023*				*2022*				*2023*				*2022*
Sales and marketing		$	69			$	61			$	209			$	202
Research and development			107				90				320				273
General and administrative			265				386				850				1,143
		$	441			$	537			$	1,379			$	1,618